Ameritas Investment Partners, Inc. Immuno Gen, Inc. Transaction History

Ameritas Investment Partners, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $8,746 - $21,024	702 Added 2.98%	24,261 $719,000
Q3 2023 Nov 13, 2023	BUY	$14.09 - $19.87 $49,554 - $69,882	3,517 Added 17.55%	23,559 $373,000
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $16,492 - $88,179	4,398 Added 28.11%	20,042 $378,000
Q1 2021 May 14, 2021	BUY	$6.5 - $10.53 $6,012 - $9,740	925 Added 6.28%	15,644 $127,000
Q2 2020 Aug 05, 2020	BUY	$3.32 - $5.34 $5,776 - $9,291	1,740 Added 13.41%	14,719 $68,000
Q1 2020 May 13, 2020	BUY	$2.12 - $6.8 $2,476 - $7,942	1,168 Added 9.89%	12,979 $44,000
Q3 2018 Nov 13, 2018	BUY	$8.6 - $11.26 $9,692 - $12,690	1,127 Added 10.55%	11,811 $112,000
Q2 2018 Aug 13, 2018	BUY	$9.52 - $12.15 $26,379 - $33,667	2,771 Added 35.02%	10,684 $104,000
Q4 2017 Feb 14, 2018	BUY	$5.07 - $7.92 $6,398 - $9,995	1,262 Added 18.97%	7,913 $51,000
Q2 2017 Aug 15, 2017	BUY	N/A	6,651	6,651 $47,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.